DREDGECAP
NASDAQ·Surgical & Medical Instruments & Apparatus
DXCM

DEXCOM INC

DEXCOM INC (ticker: DXCM) is an NASDAQ-listed surgical & medical instruments & apparatus company. Its most recent SEC filing was a 8-K dated 2026-05-15. DredgeCap's extraction of DXCM's SEC filings surfaces no active distress signals from the most recent annual filing. DXCM reported $1.19B in revenue and $199.50M for the period ending 2026-03-31, with operating cash flow of $525.60M. Cash and equivalents stood at $1.12B (up 23.6% year-over-year). Total assets of $6.63B exceed total liabilities of $3.68B. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

DXCM Overview
8-KApril 30, 20264/30/26

DXCM8-K Filing

Track for Alerts

DXCM 8-K Summary

On April 30, 2026, DEXCOM INC filed an 8-K covering Results of Operations and Financial Condition (Item 2.02) and Financial Statements and Exhibits (Item 9.01). Primary disclosure: , including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section.

8-K Items Disclosed

Item 2.02Results of Operations and Financial Condition
Quarterly or annual earnings results released. Often paired with a press release as Exhibit 99.1.
, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits
Press releases, exhibits, and supporting documents attached to this filing.
(d) Exhibits.NumberDescription99.1Press release dated April 30, 2026104Cover Page Interactive Data File (formatted as Inline XBRL)SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.DEXCOM, INC.By: /s/ JEREME SYLVAINJereme SylvainExecutive Vice President and Chief Financial Officer(Principal Financial and Accounting Officer)Date:April 30, 2026
Structured financials are not available for this filing. View the original on SEC EDGAR for details.
Current DredgeCap Risk Profile
3.2/10
MODERATE RISK
Dilution Risk
LOW2.5/10
Liquidity Risk
LOW2.0/10
Debt Toxicity
MODERATE3.5/10
Profitability Risk
LOW2.8/10
Going Concern✓ Not flagged
The risk profile above reflects the latest cached DredgeCap analysis for DXCM. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open DXCM's company page.

What is a 8-K?

A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.

More on DXCM

Dilution Analysis
Debt Structure
Going Concern
Full Financials
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.